Want to see GB:SBTX full AI Analyst Report?
SBTX Stock Chart & Stats
13.25 p
-0.88 p(-5.43%)
At close: 4:00 PM EST
13.25 p
-0.88 p(-5.43%)
Day’s Range― - ―
52-Week Range5.00 p - 23.00 p
Previous CloseN/A
Volume282.34K
Average Volume (3M)673.17K
Market Cap
£27.21M
Enterprise Value28.27M
Total Cash (Recent Filing)£3.12M
Total Debt (Recent Filing)£939.16K
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding259,168,670
10 Day Avg. Volume831,404
30 Day Avg. Volume673,172
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)4.06
Price to Sales (P/S)8.25
P/FCF Ratio-29.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£8.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high top-line growth indicates strong market demand for the company’s skin-health technology and successful early commercial traction. Over 2-6 months this growth provides operating leverage potential as sales scale, supporting future margin improvement if cost discipline continues.
Conservative Balance SheetLow leverage gives the company flexibility to fund commercialization, R&D or bridge cash flow gaps without immediate refinancing pressure. This structural conservatism reduces solvency risk over the medium term and preserves optionality for partnership or licensing investments.
Asset-Light B2B Model & IPA platform/IP-driven, partner-led commercial model scales with limited capital intensity. Licensing and ingredient supply to brand partners enable recurring, diversified revenue streams and faster route-to-market versus building a large direct-to-consumer infrastructure, supporting durable growth if partnerships multiply.
Bears Say
UnprofitabilityOngoing negative operating profitability constrains reinvestment and forces reliance on external funding. Unless margins convert to positive through scale or cost reduction, persistent losses will limit free-cash-flow generation and increase execution risk over the coming quarters.
Negative Cash FlowNegative operating and free cash flows create a structural funding requirement to sustain growth and commercialization. Over a 2-6 month horizon, continued cash burn raises refinancing or dilution risk and can restrict marketing or partner-support investments needed to convert revenue momentum into sustainable earnings.
Dependency On Partner ExecutionRevenue and scaling hinge on partners’ product launches and ongoing demand for supplied actives. This dependence limits control over market execution and timing; if partners underperform or delay launches, revenue visibility and margin expansion could be materially impaired over the medium term.
SkinBioTherapeutics News
SBTX FAQ
What was SkinBioTherapeutics PLC’s price range in the past 12 months?
SkinBioTherapeutics PLC lowest share price was 5.00 p and its highest was 23.00 p in the past 12 months.
What is SkinBioTherapeutics PLC’s market cap?
SkinBioTherapeutics PLC’s market cap is £27.21M.
When is SkinBioTherapeutics PLC’s upcoming earnings report date?
SkinBioTherapeutics PLC’s upcoming earnings report date is Dec 02, 2026 which is in 153 days.
How were SkinBioTherapeutics PLC’s earnings last quarter?
Currently, no data Available
Is SkinBioTherapeutics PLC overvalued?
According to Wall Street analysts SkinBioTherapeutics PLC’s price is currently Overvalued.
Does SkinBioTherapeutics PLC pay dividends?
SkinBioTherapeutics PLC does not currently pay dividends.
What is SkinBioTherapeutics PLC’s EPS estimate?
SkinBioTherapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SkinBioTherapeutics PLC have?
SkinBioTherapeutics PLC has 259,168,670 shares outstanding.
What happened to SkinBioTherapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SkinBioTherapeutics PLC?
Currently, no hedge funds are holding shares in GB:SBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SkinBioTherapeutics PLC
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.
Technical Analysis
ImmuPharma
―
OptiBiotix Health
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Ondine Biomedical, Inc.
―